Walleye Capital LLC Has $101,000 Stock Position in Accuray Incorporated $ARAY

Walleye Capital LLC lowered its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 62.8% in the first quarter, Holdings Channel reports. The institutional investor owned 56,421 shares of the medical equipment provider’s stock after selling 95,172 shares during the period. Walleye Capital LLC’s holdings in Accuray were worth $101,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Northern Trust Corp lifted its holdings in shares of Accuray by 0.9% during the fourth quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider’s stock worth $1,603,000 after buying an additional 7,399 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Accuray by 50.7% in the fourth quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 9,187 shares during the period. North Star Investment Management Corp. boosted its stake in shares of Accuray by 1.0% in the first quarter. North Star Investment Management Corp. now owns 1,058,545 shares of the medical equipment provider’s stock valued at $1,895,000 after buying an additional 10,000 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Accuray by 38.3% in the fourth quarter. MetLife Investment Management LLC now owns 48,234 shares of the medical equipment provider’s stock valued at $96,000 after buying an additional 13,370 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Accuray by 5.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 278,384 shares of the medical equipment provider’s stock valued at $498,000 after buying an additional 14,649 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. BTIG Research boosted their price target on Accuray from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Wall Street Zen cut Accuray from a “hold” rating to a “sell” rating in a research note on Saturday, August 30th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Accuray has an average rating of “Buy” and an average target price of $5.00.

Accuray Price Performance

Shares of ARAY opened at $1.51 on Friday. Accuray Incorporated has a one year low of $1.14 and a one year high of $2.95. The company has a market cap of $170.14 million, a P/E ratio of -75.50 and a beta of 1.26. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.65 and a quick ratio of 0.92. The firm has a 50 day simple moving average of $1.42 and a two-hundred day simple moving average of $1.55.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Wednesday, August 13th. The medical equipment provider reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Accuray had a negative net margin of 0.35% and a negative return on equity of 4.92%. The firm had revenue of $127.54 million for the quarter, compared to analyst estimates of $123.78 million. Accuray has set its FY 2026 guidance at EPS. Research analysts forecast that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.